Champions Oncology (CSBR) Q4 2026 earnings review
Margins Rebound, but Cash Burn Takes Center Stage
Champions Oncology closed FY26 with an encouraging 12% YoY revenue growth in Q4 ($13.8M) and successfully restored its oncology services margin to 51% (up from 41%). This margin expansion—driven by bringing radiopharmaceutical services in-house—helped the company post its fourth consecutive quarter of positive Adjusted EBITDA. However, this operational success is clouded by a deteriorating liquidity position. The company burned $2.2M in operating cash this quarter, driving its cash balance down to just $4.9M. With ongoing investments required for its data platform and Corellia subsidiary, execution on collections and cost discipline is now paramount.
🐂 Bull Case
The strategic in-sourcing of radiopharmaceutical work is yielding tangible results, driving gross margins up 1,000 bps YoY to 51% in Q4 and validating management's infrastructure investments.
Despite a tough biotech funding environment, core research services drove a 12% revenue increase, offsetting the absence of prior-year data licensing windfalls.
🐻 Bear Case
The cash balance halved over the fiscal year to $4.9M. An operating cash outflow of $2.2M in Q4 alone raises the specter of a potential capital raise if working capital dynamics don't quickly reverse.
Sales & Marketing and R&D expenses continue to climb as the company funds its data platform and commercial teams, limiting the bottom-line leverage from revenue growth.
⚖️ Verdict: ⚪
Neutral. The margin recovery proves management's execution on in-sourcing operations, but the shrinking cash runway and lack of forward guidance introduce financing risk that cannot be ignored.
Key Themes
Radiopharmaceutical In-Sourcing Drives Margin Recovery
A previous major concern—margin compression due to outsourced lab costs—has been decisively addressed. By transitioning radiopharmaceutical workflows into its internal proprietary labs, Champions boosted its Q4 oncology services margin to 51%, up from 41% a year ago. This structural shift transforms a fast-growing, high-demand service into a durable profit engine.
Core Research Services Anchor the Top Line
Core services showed Reversing momentum. Total FY26 revenue hit a record $59.4M, with Q4 jumping 12% YoY. This growth is particularly impressive given it fully offset the absence of a massive $4.5M data licensing deal recognized in the prior fiscal year, proving the baseline clinical research business is fundamentally healthy.
Commercial Investments in the Data Platform
Management is aggressively betting on its multi-omic functional PDX databank. Sales and marketing expenses accelerated to $2.8M (up 21% YoY) to expand the commercial capabilities across both the core services and the data platform. While suppressing near-term profits, this aims to lock in higher-margin, AI-driven drug discovery deals.
Adjusted EBITDA Hides Concerning Cash Burn
A glaring contradiction exists between the income statement and the cash flow statement. Management touted positive Adjusted EBITDA of $158K for Q4, yet operating cash flow was deeply negative at -$2.2M. The company cited 'working capital timing' and 'timing of customer collections,' but with zero debt and total cash down to just $4.9M, the liquidity buffer is dangerously thin.
Data Deal Lulls Expose Reliance on Services
No major data licensing transactions were announced for Q4. The data business remains highly lumpy. Without large 6- or 7-figure licensing deals closing consistently, the burden of funding the expanding OpEx base falls entirely on the traditional services business.
Resilience in a Constrained Biopharma Market
Achieving 12% YoY revenue growth signals that Champions is successfully navigating a tight biotech funding environment. The macro backdrop remains cautious, but the company appears to be capturing a larger share of outsourced R&D budgets from more resilient large pharma clients.
Other KPIs
Reversing. A massive swing from the $7.4M provided by operating activities in FY25. This $11.8M year-over-year reversal was driven primarily by a reduction in deferred revenue and an increase in accounts receivable, highlighting poor cash conversion cycles.
Stable. Up slightly from $2.0M in the prior year, bringing the full-year total to $9.1M (+33% YoY). The elevated baseline reflects continuous investments in sequencing and laboratory costs for the data platform, as well as ongoing development of Corellia's technology.
Guidance
Stable. Management did not provide specific revenue or earnings guidance in the Q4 release, opting instead for qualitative statements about remaining 'focused on building on this momentum' and allocating capital prudently. The lack of concrete targets limits visibility into the pace of data platform monetization.
Key Questions
Cash Runway and Liquidity
With the cash balance down to $4.9M and $2.2M burned in Q4 operations, are you exploring non-dilutive funding options, or do you expect working capital timing and collections to fully reverse in Q1?
Structural Margin Ceiling
Given the impressive 1,000 bps YoY expansion in oncology services margin to 51%, what is the structural ceiling for this margin now that radiopharmaceutical activities are largely operating in-house?
Corellia Spin-Off Timeline
Corellia technology was mentioned as a continuing strategic initiative. Are you still actively seeking external VC funding to take this subsidiary off your P&L, and what is the realistic timeline for a transaction?
Data Pipeline Visibility
Can you provide an update on the pipeline for large-scale data licensing deals? Should investors expect the lumpiness of this segment to smooth out in FY27?